These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 22036874)

  • 1. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
    Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
    Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.
    Eisenhofer G; Lenders JW; Timmers H; Mannelli M; Grebe SK; Hofbauer LC; Bornstein SR; Tiebel O; Adams K; Bratslavsky G; Linehan WM; Pacak K
    Clin Chem; 2011 Mar; 57(3):411-20. PubMed ID: 21262951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma.
    Sue M; Martucci V; Frey F; Lenders JM; Timmers HJ; Peczkowska M; Prejbisz A; Swantje B; Bornstein SR; Arlt W; Fassnacht M; Beuschlein F; Robledo M; Pacak K; Eisenhofer G
    Eur J Endocrinol; 2015 Feb; 172(2):89-95. PubMed ID: 25371406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.
    Rao D; Peitzsch M; Prejbisz A; Hanus K; Fassnacht M; Beuschlein F; Brugger C; Fliedner S; Langton K; Pamporaki C; Gudziol V; Stell A; Januszewicz A; Timmers HJLM; Lenders JWM; Eisenhofer G
    Eur J Endocrinol; 2017 Aug; 177(2):103-113. PubMed ID: 28476870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
    King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
    J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic pheochromocytoma and paraganglioma.
    Angelousi A; Kassi E; Zografos G; Kaltsas G
    Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phaeochromocytoma: a catecholamine and oxidative stress disorder.
    Pacak K
    Endocr Regul; 2011 Apr; 45(2):65-90. PubMed ID: 21615192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma.
    Peitzsch M; Prejbisz A; Kroiß M; Beuschlein F; Arlt W; Januszewicz A; Siegert G; Eisenhofer G
    Ann Clin Biochem; 2013 Mar; 50(Pt 2):147-55. PubMed ID: 23512172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.
    Pamporaki C; Prodanov T; Meuter L; Berends AMA; Bechmann N; Constantinescu G; Beuschlein F; Remde H; Januszewicz A; Kerstens MN; Timmers HJLM; Taïeb D; Robledo M; Lenders JWM; Pacak K; Eisenhofer G
    Eur J Cancer; 2022 Jul; 169():32-41. PubMed ID: 35500459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
    Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
    Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
    Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study.
    Park SS; Ahn CH; Lee S; Lee W; Kim WW; Lee YM; Kim SJ; Sung TY; Lee KE; Kim JH; Lee SH; Koh JM
    J Intern Med; 2024 Jul; 296(1):68-79. PubMed ID: 38659304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes
    Andrews KA; Ascher DB; Pires DEV; Barnes DR; Vialard L; Casey RT; Bradshaw N; Adlard J; Aylwin S; Brennan P; Brewer C; Cole T; Cook JA; Davidson R; Donaldson A; Fryer A; Greenhalgh L; Hodgson SV; Irving R; Lalloo F; McConachie M; McConnell VPM; Morrison PJ; Murday V; Park SM; Simpson HL; Snape K; Stewart S; Tomkins SE; Wallis Y; Izatt L; Goudie D; Lindsay RS; Perry CG; Woodward ER; Antoniou AC; Maher ER
    J Med Genet; 2018 Jun; 55(6):384-394. PubMed ID: 29386252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma.
    van Berkel A; Lenders JW; Timmers HJ
    Eur J Endocrinol; 2014 Mar; 170(3):R109-19. PubMed ID: 24347425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
    Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
    J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.